Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

PSORIATIC ARTHRITIS

Guselkumab effective through 2 years in PsA trial

Nature Reviews Rheumatology volume 18, page 4 (2022)Cite this article

Subjects

New results from the phase III DISCOVER-2 trial (n = 739) indicate that the benefits of continued treatment with guselkumab are maintained over 2 years in patients with active psoriatic arthritis (PsA) and no previous biologic DMARD therapy. Treatment with guselkumab, which targets the p19 subunit of IL-23, improved several disease domains including skin and joint symptoms, with similar response rates across both treatment regimens assessed (guselkumab 100 mg every 4 or 8 weeks). Rates of radiographic progression remained low and no new safety signals were observed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

  • McInnes, I. B. et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through 2 years: results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. https://doi.org/10.1002/art.42010 (2021)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Rheumatology http://www.nature.com/nrrheum/

    Sarah Onuora

Authors
  1. Sarah Onuora
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah Onuora.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Onuora, S. Guselkumab effective through 2 years in PsA trial. Nat Rev Rheumatol 18, 4 (2022). https://doi.org/10.1038/s41584-021-00733-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-021-00733-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing